Portal de Periódicos da CAPES

Tocilizumab as an Adjuvant Therapy for Hemophagocytic Lymphohistiocytosis Associated With Visceral Leishmaniasis

2015; Lippincott Williams & Wilkins; Volume: 23; Issue: 5 Linguagem: Inglês

10.1097/mjt.0000000000000035

1536-3686

Raquel Ríos-Fernández, José Luis Callejas‐Rubio, Sonia García‐Rodríguez, Jaime Sancho, Mercedes Zubiaur, Norberto Ortego‐Centeno,

Kawasaki Disease and Coronary Complications

Leishmaniasis is important as a cause of hemophagocytic lymphohistiocytosis (HLH) and must be considered and excluded in patients with HLH because it can cause severe or even fatal complications. When HLH is present, there is a deficient downregulation of the immune response, leading to an uncontrolled inflammation. We report a case of visceral leishmaniasis-HLH where the therapy with tocilizumab, targeting interleukin 6, help to regulate the immune response for the infection of Leishmania.